SCHEMBL1109422

SCHEMBL1109422

CCCCCNCc1ccc(-c2ccc(C(=O)N[C@H](C(=O)NO)[C@@H](C)O)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.52
HRH3 Q9Y5N1 1/20 0.52
PPARG P37231 1/20 0.50
HDAC1 Q13547 3/20 0.47
HDAC2 Q92769 3/20 0.47
HDAC8 Q9BY41 3/20 0.47
HDAC3 O15379 2/20 0.47
S1PR2 O95136 3/20 0.46
S1PR1 P21453 3/20 0.46
S1PR3 Q99500 3/20 0.46
LPAR2 Q9HBW0 3/20 0.46
HDAC11 Q96DB2 1/20 0.46
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1109572 0.99 PPARG (0.52) HRH4HRH3PPARGHDAC1HDAC2
SCHEMBL1109450 0.97 PPARG (0.48) HRH4HRH3PPARGHDAC1HDAC2
SCHEMBL403434 0.96 PPARG (0.55) HRH4HRH3PPARGHDAC1HDAC2
SCHEMBL1109570 0.92 PPARG (0.45) PPARGHDAC1HDAC2HDAC8HDAC3
SCHEMBL404808 0.91 PPARG (0.50) PPARGS1PR2S1PR1S1PR3LPAR2
SCHEMBL1109579 0.90 MCHR1 (0.42) PPARGHDAC1HDAC2HDAC8HDAC3
SCHEMBL404123 0.90 PPARG (0.52) PPARGS1PR2S1PR1S1PR3LPAR2
SCHEMBL1912267 0.89 HDAC1 (0.47) PPARGHDAC1CYP1A2CYP2C19LMNA
SCHEMBL1109543 0.89 HDAC1 (0.43) HRH4HRH3PPARGHDAC1
SCHEMBL1109576 0.88 HDAC6 (0.50) PPARGHDAC1CYP1A2CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153843-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2012-04-10 US disclosed
US-8101640-B2 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-01-24 US disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-7989660-B2 BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2011-08-02 US disclosed
US-20110172174-A1 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS INC. 2011-07-14 US disclosed
US-20100324025-A1 Antibacterial Agents UNIVERSITY OF WASHINGTON (US) 2010-12-23 US disclosed
US-20090247506-A1 Antibacterial agents CHIRON CORPORATION 2009-10-01 US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 US disclosed
US-20080269221-A1 ANTIBACTERIAL AGENTS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-10-30 US disclosed
US-7358359-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2008-04-15 US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244197-A1 Antibacterial agents MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885
US-20090247506-A1 Antibacterial agents MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885
US-20110172174-A1 Antibacterial agents MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885
US-20080269221-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885
US-20090163496-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885
US-20100324025-A1 Antibacterial Agents MRPL21, SI, PGLS HRH4 3744/4885HRH3 4195/4885PPARG 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.